Farxiga (generic: Dapagliflozin), is a type 2 diabetes medication that inhibits SGLT2 from transporting glucose to the kidney – assisting the body in eliminating these proteins through the urine. Studies conducted by the FDA have found only minor improvements when Faxiga is compared to placebos. More worrisome, these studies have shown Fraxiga increases risks for:
- Heart attack and stroke
- Liver failure
- Malignant tumors, including breast cancer
- Bladder cancer
In fact, these concerns were significant enough to see the FDA advisory panel recommend against approval in 2011. Bladder cancer risks alone are known to be 5x higher in patients who have used Fraxiga and similar drugs. Nonetheless, in 2014, the drug was approved for adults with type 2 diabetes in the United States.
In May of 2015, the FDA issued a warning regarding Farxiga and other SGLT2 medications linked to increased risks for diabetic ketoacidosis. In June of 2016, the agency strengthened its warnings for Farxiga and related medications due to increased risks for acute kidney injury. Information on the deadly side-effects of the SGLT2 medications continues to compound, yet the drugs are still readily available and frequently prescribed.
At this time, GoldenbergLaw is no longer accepting Farxiga cases.
Located in Minneapolis, GoldenbergLaw welcomes clients from all areas of Minnesota and throughout the nation.